Cancer / Oncology/IDH-mutant glioma
Central nervous system · subtype
IDH-mutant glioma
Subtype of Brain tumors
Clinical / Scientific
IDH1/2 mutations produce 2-hydroxyglutarate, remodel epigenetics (G-CIMP) and define a biologically distinct, usually slower glioma. They should not inherit IDH-wildtype GBM maps uncritically. IDH inhibitors are a molecular class in selected disease.
Core Biological Drivers
IDH1/2
2-HG oncometabolite.
G-CIMP epigenetics
Hypermethylator phenotype.
Key Pathways
Scientific explanation
Folate-methionine cycles supply nucleotides and methylation. Some tumours show methionine dependence and PHGDH or SHMT rewiring.
Scientific explanation
TP53 encodes a stress-responsive factor controlling cell-cycle arrest, and metabolic adaptation. Loss or mutation is among the most common cancer events.
Scientific explanation
phosphorylates PIP2 to PIP3, recruiting . supports growth, survival, glucose uptake and mTORC1 input. Pathway activation is common via PIK3CA mutation, PTEN loss or -tyrosine- signalling.
Scientific explanation
Aerobic (Warburg metabolism) supports ATP, biomass and redox buffering even when oxygen is available. Hexokinase, PKM2 and lactate export are frequent nodes.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Energy stress
Energetic stress activates AMPK, which can restrain mTORC1. Biguanides and related tools map onto this axis in models.
Mitochondrial stress
Electron-transport stress raises ROS; NRF2-driven transcription can buffer that stress and support survival. Antioxidant interventions are dual-edged.
Metabolic Vulnerabilities
2-HG inhibits αKG-dependent dioxygenases, locking an epigenetic state.
Tumor Microenvironment
Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.
Metastasis Module
Still largely neuraxis-confined.
Resistance Biology
Progression with CDKN2A loss or histologic malignant transformation.
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Target / Mechanism
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Cancer relevance
activation and restraint provide a metabolic rationale in - and -linked tumours. Human data are mixed and do not establish metformin as cancer therapy.
Metabolic adjunctive research context. Convergence: AMPK, mTOR, Glycolysis.
Target / Mechanism
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Cancer relevance
disruption can trigger mitotic stress and in cell and animal models. This is not an established oncology use.
Experimental antimitotic / microtubule stress. Convergence: Apoptosis, p53.
Research Context
- GBM TCGA. Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. https://doi.org/10.1016/j.cell.2013.09.034
- Hallmarks. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.